Latest News

In early June 2026, Welltower Inc. announced that it expects to raise its quarterly common stock dividend to US$0.85 per share from the second quarter of 2026, while also disclosing that shareholders rejected its say-on-pay proposal amid governance concerns highlighted by activist investor Jonathan Litt’s Land & Buildings campaign. This combination of a sizeable dividend increase and a forceful shareholder rebuke on executive compensation puts Welltower’s capital allocation priorities and...

In recent weeks, EMCOR Group has attracted upbeat analyst coverage, with firms such as Oppenheimer, Baird, William Blair and Zacks highlighting its record Remaining Performance Obligations backlog, strong first-quarter operational performance, and exposure to high-tech manufacturing and data center projects. This wave of positive research attention, combined with modest upward revisions to earnings estimates and a predominantly Buy-oriented recommendation base, underscores how EMCOR’s scale...

Parker-Hannifin recently agreed to acquire CIRCOR Aerospace from KKR and CIRCOR International for US$2.55 billion, while also reporting quarterly results that combined double-digit revenue growth with an adjusted operating income shortfall versus analyst expectations. At the same time, analyst commentary and insider trading disclosures highlight a company balancing strong aerospace demand and order momentum with execution questions around margins and capital allocation. Next, we will examine...

ProPetro Holding (PUMP) is in the middle of a business pivot toward AI data center infrastructure and independent microgrid power, highlighted by a framework agreement with Caterpillar for up to 2.1 gigawatts of advanced generation capacity. See our latest analysis for ProPetro Holding. The stock’s momentum has been strong, with a 29.68% 90 day share price return contributing to a 66.40% year to date share price gain and a 1 year total shareholder return of 187.68%, even as the recent board...

EBOS Group (NZSE:EBO) is back in focus after analysts maintained a Buy stance on the stock while the company reported higher quarterly revenue and net profit compared with the same period a year earlier. See our latest analysis for EBOS Group. The recent analyst support and quarterly results come after a tough run for investors, with the share price down 29.1% year to date and the 1 year total shareholder return declining 46.2%. This suggests sentiment is still rebuilding despite the latest...

Recent performance snapshot for Piper Sandler Companies (PIPR) Piper Sandler Companies (PIPR) has recently drawn investor attention after a period of mixed share performance, with the stock down over the past month but slightly higher across the past 3 months. See our latest analysis for Piper Sandler Companies. Despite a recent cooling in momentum, with the 7 day share price return down 4.35% and the year to date share price return down 13.56%, Piper Sandler still shows a stronger longer...

PICC Property and Casualty (SEHK:2328) has set out its 2025 final dividend timetable at RMB 0.44 per share and clarified withholding tax treatment for different non resident H shareholders, including Stock Connect investors. See our latest analysis for PICC Property and Casualty. At a share price of HK$14.27, PICC Property and Casualty’s stock has slipped year to date with a decline of 13.67% on a share price return basis, even as the 5 year total shareholder return of 156.16% points to a...

Ziff Davis (ZD) just reported Q1 results with lower revenue and adjusted EBITDA, weighed down by Tech & Shopping, while management pushed ahead with asset sales, share repurchases, and greater use of AI across its portfolio. See our latest analysis for Ziff Davis. At a share price of US$44.54, Ziff Davis has given shareholders a 31.04% year to date share price return and a 36.25% total shareholder return over one year. However, the 3 year and 5 year total shareholder returns are down 33.70%...

BridgeBio Pharma announced that the FDA previously accepted and granted Priority Review to its New Drug Application for oral BBP-418 in LGMD2I/R9, setting a PDUFA target action date of November 27, 2026, without planning an advisory committee meeting. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and any limb-girdle muscular dystrophy, potentially qualifying BridgeBio for a Priority Review Voucher and opening up further rare disease development paths. We’ll now examine how...

Ituran Location and Control (ITRN) is drawing attention after first quarter 2026 earnings, paired with a new dividend, updates on share repurchases, and a fresh shelf registration filing that expands future funding options. See our latest analysis for Ituran Location and Control. Those capital moves and the stronger first quarter backdrop come after a powerful run in the stock, with the share price up 52.99% year to date and an 83.48% total shareholder return over the past year, pointing to...

Strive (ASST) stock has drawn attention after a recent pullback, with the price down 8.6% in the past day and 17.3% over the past week. This has prompted closer scrutiny from investors. See our latest analysis for Strive. Despite the sharp 1-day and 7-day share price declines, Strive’s 90-day share price return of 59.35% reflects earlier momentum that has recently faded, with the year-to-date share price return now down 14.76%. If Strive’s swings have you thinking about diversification, this...

UGI Corporation recently released its 2025 ESG Report, confirming it met all of its stated 2025 ESG commitments and highlighting progress on emissions reductions, safety metrics, board independence and AI governance, while the Pennsylvania Public Utility Commission scheduled public hearings on UGI Utilities’ proposed US$17.3 million annual electric rate increase that could lift typical residential bills by 12.8%. Together, the rate case hearings and the company’s comprehensive ESG...

Murphy Oil Corporation recently presented at the Bank of America Energy & Power Credit Conference in New York, following quarterly results that showed revenue growing 10.2% year on year and beating analyst expectations while EBITDA fell short. The contrast between stronger-than-expected sales and weaker profitability, alongside management’s focus on progress at Lac Da Vang in Vietnam and the Chinook #8 Gulf of Mexico well, highlights how project execution and cost control are becoming...

In its recently reported fiscal third-quarter 2026, Fabrinet posted strong year-over-year revenue growth in Optical Communications, highlighted by record telecom sales and reiterated expectations for continued growth despite near-term datacom supply constraints. The company also announced a minority investment in Raytek Semiconductor, deepening its involvement in co-packaged optics and enabling closer ties with hyperscaler customers through more advanced packaging and direct transceiver...

Victoria's Secret (VSXY) is back in focus after first quarter results beat sales and earnings expectations, lifted by broad-based growth, strong customer acquisition, and a higher full-year outlook that helped reset investor sentiment. See our latest analysis for Victoria's Secret. At a share price of $78.96, Victoria's Secret has seen strong momentum, with a 57.04% 30 day share price return and a very large 1 year total shareholder return that reflects how rapidly sentiment has shifted after...

BorgWarner recently reported strong first-quarter 2026 results, reaffirmed its full-year guidance, highlighted new awards in electrified and industrial power solutions, and outlined plans to scale data center and grid-related products from 2027 onward. At the same time, the company is sharpening its technology leadership with the upcoming appointment of long-time PowerDrive Systems head Stefan Demmerle as Chief Technology Officer, signaling a tighter focus on electrified propulsion and...

Why Chugai Pharmaceutical Stock Is Drawing Attention Now Recent share price moves have pushed Chugai Pharmaceutical (TSE:4519) further away from its recent highs, which is prompting some investors to recheck the fundamentals behind this large Japan based pharmaceutical group. See our latest analysis for Chugai Pharmaceutical. At a share price of ¥7,567, Chugai Pharmaceutical has seen its short term momentum fade, with the 30 day share price return down 8.22% and the 90 day share price return...

Recent performance snapshot Bio-Techne (TECH) has drawn attention after a recent single day gain of 2.2%. The stock remains down about 7% over the past month and roughly 9% over the past 3 months. See our latest analysis for Bio-Techne. At a share price of US$50.85, Bio-Techne has seen short term momentum pick up, with a 7 day share price return of 5.74% following a weaker 30 day and year to date share price performance. The 1 year total shareholder return of 2.62% contrasts with declines...

CSG (ENXTAM:CSG) is back in focus after announcing two long term contracts to supply mechanical and electronic fuzes for large calibre ammunition to NATO country customers, with a total value in the high tens of millions of euros. See our latest analysis for CSG. Despite the new fuze contracts and the recently announced Fuchs Electronics Europe venture, CSG’s short term share price return has come under pressure. The 7 day share price return is down 12.41% and the 90 day share price return is...

Wells Fargo’s recent upgrade of Enterprise Products Partners (EPD) puts fresh attention on how its midstream assets and expansion projects intersect with rising U.S. liquefied petroleum gas exports and shifting European and Asian energy demand. See our latest analysis for Enterprise Products Partners. EPD’s share price return of 18.13% year to date and 1-year total shareholder return of 31.60% suggest momentum that aligns with Wells Fargo’s upgrade and recent commentary around Permian driven...

Amneal Pharmaceuticals recently received U.S. Food and Drug Administration approval for its romidepsin injection solution, a ready-to-use 27.5 mg/5.5 mL oncology therapy granted Competitive Generic Therapy designation and 180 days of market exclusivity. This approval not only returns an important treatment option for cutaneous T-cell lymphoma to the market but also underscores Amneal’s industry-leading track record in securing CGT approvals for complex generics. Next, we will examine how...

In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.

The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities, typically in smaller or newer companies. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, giving investors the chance to discover hidden value in quality companies.

Over the last 7 days, the United States market has remained flat, though it has seen a significant rise of 26% over the past year, with earnings forecasted to grow by 17% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.